A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants
Status:
Completed
Trial end date:
2021-05-17
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the effect of selpercatinib on the levels of
dabigatran in the blood stream and how long it takes the body to remove dabigatran. This
study will also look at how safe and well-tolerated of dabigatran when administered in
combination with selpercatinib in healthy participants. This study will last approximately 22
to 25 days.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company Loxo Oncology, Inc.
Collaborators:
Eli Lilly and Company Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company